The effect of a lifestyle risk reduction intervention on lifestyle adherence and health‐related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomes

2019 ◽  
Vol 28 (4) ◽  
pp. 920-923
Author(s):  
Mary E. Cooley ◽  
Traci M. Blonquist ◽  
Fangxin Hong ◽  
Manan M. Nayak ◽  
Scott E. Crouter ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Lifestyle Risk ◽  
Risk Reduction Intervention ◽  
Lifestyle Risk Reduction

scholarly journals Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132568 ◽  
Author(s):  
Christine Rotonda ◽  
Amélie Anota ◽  
Mariette Mercier ◽  
Bérangère Bastien ◽  
Gisèle Lacoste ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Clinical Trial ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Health Related Quality ◽  
Small Cell Lung ◽  
Related Quality ◽  
Health Related

scholarly journals OC-0320: Pre-radiotherapy health related quality of life assessment associates with survival in lung cancer patients

2015 ◽  
Vol 115 ◽  
pp. S160
Author(s):  
S. Perez-Luque ◽  
J. Cacicedo ◽  
L. Delgado Arroniz ◽  
J.M. Praena-Fernandez ◽  
E. Montero ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Life Assessment ◽  
Health Related Quality ◽  
Quality Of Life Assessment ◽  
Lung Cancer Patients ◽  
Related Quality ◽  
Health Related

scholarly journals Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study

2019 ◽  
Vol 30 ◽  
pp. ii48
Author(s):  
M. Pérol ◽  
A. Dixmier ◽  
F. Barlesi ◽  
D. Debieuvre ◽  
C. Raspaud ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Real Life ◽  
Small Cell ◽  
Health Related Quality ◽  
Small Cell Lung ◽  
Related Quality ◽  
Health Related ◽  
Nsclc Patients

scholarly journals Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer

2020 ◽  
Vol 38 (3) ◽  
pp. 271-280 ◽  
Author(s):  
Julien Mazieres ◽  
Dariusz Kowalski ◽  
Alexander Luft ◽  
David Vicente ◽  
Ali Tafreshi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Combination Group ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Small Cell Lung ◽  
Quality Of Life Questionnaire ◽  
Related Quality ◽  
Health Related

PURPOSE In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response rate in patients with previously untreated metastatic squamous non–small-cell lung cancer (NSCLC), with little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407. METHODS Patients were randomly assigned to receive 4 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus carboplatin plus paclitaxel or nab-paclitaxel, followed by pembrolizumab or placebo for an additional 31 cycles. Health-related quality of life (HRQoL) was evaluated using the European Organisation for Research and Treatment of Cancer Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and Quality of Life Questionnaire-Lung Cancer Module 13 (QLQ-LC13). Key PRO endpoints were change from baseline to weeks 9 and 18 (during and after platinum therapy) in the QLQ-C30 global health status/quality of life (GHS/QoL) score and time to deterioration in the composite endpoint of cough, chest pain, or dyspnea from the QLQ-C30 and QLQ-LC13. Two-sided, nominal P values are provided. RESULTS A total of 554 and 553 patients completed ≥ 1 QLQ-C30 or ≥ 1 QLQ-LC13 assessment, respectively. GHS/QoL score improved for the pembrolizumab-combination group (least squares [LS] mean [95% CI] change from baseline: week 9, 1.8 [−0.9 to 4.4]; week 18, 4.3 [1.7 to 6.9]) and deteriorated in the placebo-combination group (week 9, −1.8 [−4.4 to 0.7]; week 18, −0.57 [−3.3 to 2.2]). Between-group differences were improved for the pembrolizumab-combination group (difference in LS mean scores: week 9, 3.6 [95% CI, 0.3 to 6.9], nominal P = .0337; week 18, 4.9 [1.4 to 8.3], nominal P = .0060). Median time to deterioration in cough, chest pain, or dyspnea was not reached in either group (hazard ratio, 0.79; 95% CI, 0.58 to 1.06]; nominal P = .125). CONCLUSION Addition of pembrolizumab to chemotherapy maintained or improved HRQoL measurements relative to baseline and improved HRQoL versus chemotherapy alone at weeks 9 and 18. These results support use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC.

Sign in / Sign up

Export Citation Format

Share Document